Our results identify drug repurposing of belimumab for neutralization of BAFF to complement small molecule inhibitor treatment as a promising therapeutic approach in CLL that is presently undergoing clinical evaluation. Here, TNFSF13B is linked to B-cell chronic lymphocytic leukemia.